Cargando…

miR-362-3p suppresses ovarian cancer by inhibiting LRP8

BACKGROUND: Ovarian cancer is one of the most common female cancers, with a high incidence worldwide. Aberrant expression of low‐density lipoprotein (LDL) receptor‐related protein 8 (LRP8) and microRNA (miR)-362-3p is involved in the pathogenesis of different cancers. METHODS: We aimed to elucidate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chun, Yang, Yi, Wang, Huimin, Song, Yu, Huang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636862/
https://www.ncbi.nlm.nih.gov/pubmed/34839107
http://dx.doi.org/10.1016/j.tranon.2021.101284
_version_ 1784608620601671680
author Li, Chun
Yang, Yi
Wang, Huimin
Song, Yu
Huang, Huan
author_facet Li, Chun
Yang, Yi
Wang, Huimin
Song, Yu
Huang, Huan
author_sort Li, Chun
collection PubMed
description BACKGROUND: Ovarian cancer is one of the most common female cancers, with a high incidence worldwide. Aberrant expression of low‐density lipoprotein (LDL) receptor‐related protein 8 (LRP8) and microRNA (miR)-362-3p is involved in the pathogenesis of different cancers. METHODS: We aimed to elucidate the underlying mechanism of the miR-362-3p-LRP8 axis in ovarian cancer. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to examine miR-362-3p and LRP8 expression in ovarian cancer tissues and cells. The luciferase assay was used to determine the relationship between miR-362-3p and LRP8. The function of overexpression of miR-362-3p and LRP8 was determined by assessing the cell viability using the cell counting kit 8 (CCK-8) assay, proliferation using 5′‑bromo-2′-deoxyuridine (BrdU) assay, migration using wound healing assay, invasion using transwell assay, and the protein expression levels of matrix metalloproteinase (MMP)-2, MMP9, and integrin α5 or β1 using western blotting assays in ovarian cancer cells. RESULTS: miR-362-3p expression levels were decreased in ovarian cancer tissues and cells and negatively correlated with LRP8 levels. Overexpression of miR-362-3p dramatically repressed cell growth. Furthermore, overexpression of LRP8 significantly facilitated the proliferation, migration, and invasion of ovarian cancer cells, which counteracted the inhibitory effect of miR-362-3p on ovarian cancer cell growth. CONCLUSIONS: We reported that miR-362-3p hampered cell growth by repressing LRP8 expression in ovarian cancer cells. Our results provide new insights into ovarian cancer, involving both miR-362-3p and LRP8, which can be used as potential biomarkers for the treatment of ovarian cancer.
format Online
Article
Text
id pubmed-8636862
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-86368622021-12-16 miR-362-3p suppresses ovarian cancer by inhibiting LRP8 Li, Chun Yang, Yi Wang, Huimin Song, Yu Huang, Huan Transl Oncol Original Research BACKGROUND: Ovarian cancer is one of the most common female cancers, with a high incidence worldwide. Aberrant expression of low‐density lipoprotein (LDL) receptor‐related protein 8 (LRP8) and microRNA (miR)-362-3p is involved in the pathogenesis of different cancers. METHODS: We aimed to elucidate the underlying mechanism of the miR-362-3p-LRP8 axis in ovarian cancer. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to examine miR-362-3p and LRP8 expression in ovarian cancer tissues and cells. The luciferase assay was used to determine the relationship between miR-362-3p and LRP8. The function of overexpression of miR-362-3p and LRP8 was determined by assessing the cell viability using the cell counting kit 8 (CCK-8) assay, proliferation using 5′‑bromo-2′-deoxyuridine (BrdU) assay, migration using wound healing assay, invasion using transwell assay, and the protein expression levels of matrix metalloproteinase (MMP)-2, MMP9, and integrin α5 or β1 using western blotting assays in ovarian cancer cells. RESULTS: miR-362-3p expression levels were decreased in ovarian cancer tissues and cells and negatively correlated with LRP8 levels. Overexpression of miR-362-3p dramatically repressed cell growth. Furthermore, overexpression of LRP8 significantly facilitated the proliferation, migration, and invasion of ovarian cancer cells, which counteracted the inhibitory effect of miR-362-3p on ovarian cancer cell growth. CONCLUSIONS: We reported that miR-362-3p hampered cell growth by repressing LRP8 expression in ovarian cancer cells. Our results provide new insights into ovarian cancer, involving both miR-362-3p and LRP8, which can be used as potential biomarkers for the treatment of ovarian cancer. Neoplasia Press 2021-11-26 /pmc/articles/PMC8636862/ /pubmed/34839107 http://dx.doi.org/10.1016/j.tranon.2021.101284 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Li, Chun
Yang, Yi
Wang, Huimin
Song, Yu
Huang, Huan
miR-362-3p suppresses ovarian cancer by inhibiting LRP8
title miR-362-3p suppresses ovarian cancer by inhibiting LRP8
title_full miR-362-3p suppresses ovarian cancer by inhibiting LRP8
title_fullStr miR-362-3p suppresses ovarian cancer by inhibiting LRP8
title_full_unstemmed miR-362-3p suppresses ovarian cancer by inhibiting LRP8
title_short miR-362-3p suppresses ovarian cancer by inhibiting LRP8
title_sort mir-362-3p suppresses ovarian cancer by inhibiting lrp8
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636862/
https://www.ncbi.nlm.nih.gov/pubmed/34839107
http://dx.doi.org/10.1016/j.tranon.2021.101284
work_keys_str_mv AT lichun mir3623psuppressesovariancancerbyinhibitinglrp8
AT yangyi mir3623psuppressesovariancancerbyinhibitinglrp8
AT wanghuimin mir3623psuppressesovariancancerbyinhibitinglrp8
AT songyu mir3623psuppressesovariancancerbyinhibitinglrp8
AT huanghuan mir3623psuppressesovariancancerbyinhibitinglrp8